Star Entertainment can add new claims to a dispute over renovations at its Sydney casino, despite the fact that the defendant builder may be time barred from deflecting liability onto a subcontractor.
Erin Molan will receive zero damages under a settlement reached with the Daily Mail, after the Full Federal Court set aside a $150,000 defamation judgment for the sports presenter and sent the case back for a new trial.
Westpac has hit back at a bid by ASIC to add an allegation to the regulator’s insider trading case that hinges on the bank providing financial services when it traded on the morning of a $16 billion deal to privatise electricity provider Ausgrid.
Leading defamation lawyer Patrick George has joined Company (Giles), reuniting with former protégé Rebekah Giles after leaving the law firm he founded 17 years ago.
Eleven current and former Star Entertainment executives have refuted ASIC’s claims that they breached their duties in relation to the casino operator’s lax money laundering compliance, with all but two denying they had a duty to ensure the company complied with its legal obligations.
Insurer Bond & Credit Company has overcome an administrator’s protests and won leave to bring cross-claims against three Greensill entities in lawsuits over the financing firm’s $1.7 billion collapse.
A shareholder class action against Medibank has claimed it did not disclose “serious deficiencies” in its cybersecurity measures, including failing to implement security measures such as multi factor authentication, causing investors to buy shares at inflated prices.
Australia’s largest private health insurer Medibank has been hit with a shareholder class action in the wake of a massive cyberattack that left the data of 10 million customers exposed.
The NSW state racing authority has won access to communications between public relations firm Cato & Clive and five other racing bodies, including Racing Victoria, as it weighs a lawsuit alleging they plotted to exclude the body from the Australian horseracing industry.
A unit of Purdue Pharma has fired off a cross-claim in Australian drug maker AUPharma’s lawsuit alleging the US drug giant was wrongly granted patent extensions for oxycodone products marketed as Targin.